OKYO 1.02 OKYO Pharma Limited
| Range: | 0.808-2.12 | Vol Avg: | 184598 | Last Div: | 0 | Changes: | -0.01 |
| Beta: | -3.38 | Cap: | 0.03B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue May 17 2022 | Empoloyees: | 8 | ||
| CUSIP: | 679345108 | CIK: | 0001849296 | ISIN: | US6793451088 | Country: | GB |
| CEO: | Dr. Gary S. Jacob Ph.D. | Website: | https://www.okyopharma.com | ||||
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow